标题
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2021-01-06
DOI
10.2217/fon-2020-0727
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer
- (2020) Deepika Singh et al. PATHOLOGY
- TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies
- (2020) Hassan Dianat-Moghadam et al. PHARMACOLOGICAL RESEARCH
- PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR
- (2020) Jinqi Lv et al. Frontiers in Oncology
- Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission
- (2020) Bin Wu et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo
- (2020) Ze Tao et al. BIOMACROMOLECULES
- TRAIL therapy and prospective developments for cancer treatment
- (2020) Bindu Thapa et al. JOURNAL OF CONTROLLED RELEASE
- Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
- (2019) Agathe Dubuisson et al. Cell Death & Disease
- Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein
- (2019) Wenjia Ma et al. Aging-US
- Targeting TRAIL
- (2019) George Nicolae Daniel Ion et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
- (2019) Mohammed I. Y. Elmallah et al. Cancers
- TRAIL-based gene delivery and therapeutic strategies
- (2019) Hui-hai Zhong et al. ACTA PHARMACOLOGICA SINICA
- Metal‐based phosphorus dendrimers as novel nanotherapeutic strategies to tackle cancers: A concise overview
- (2019) Liang Chen et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- The TRAIL to cancer therapy: Hindrances and potential solutions
- (2019) Sonia How Ming Wong et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1
- (2019) Markus Krebs et al. Biomed Research International
- Developing TRAIL/TRAIL death receptor-based cancer therapies
- (2018) Xun Yuan et al. CANCER AND METASTASIS REVIEWS
- Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations
- (2018) Spyridon Tsikalakis et al. PATHOLOGY RESEARCH AND PRACTICE
- The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
- (2018) Karen Legler et al. Cell Death & Disease
- Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes
- (2018) Neila Chekkat et al. Oncotarget
- Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC
- (2018) Jan-Paul Gundlach et al. BMC CANCER
- Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy
- (2017) Xu Wu et al. Nanoscale
- TRAIL–NP hybrids for cancer therapy: a review
- (2017) H. Belkahla et al. Nanoscale
- Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
- (2017) Linda J.W. Bosch et al. Oncotarget
- ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
- (2017) Xun Yuan et al. Oncotarget
- Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy
- (2017) Ling Li et al. Theranostics
- Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo
- (2017) Haipeng Liu et al. Scientific Reports
- Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma
- (2016) Ling Li et al. BIOMATERIALS
- Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer
- (2016) Juan Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
- (2016) Filiz Senbabaoglu et al. CANCER BIOLOGY & THERAPY
- Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer
- (2016) Ufuk Mert et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
- (2016) Jie Yang et al. MOLECULAR CANCER THERAPEUTICS
- Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway
- (2016) Weiping Zhu et al. ONCOLOGY REPORTS
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors
- (2016) Andrew B. Hill et al. TRENDS IN BIOTECHNOLOGY
- Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation
- (2016) Lei Chen et al. Cell Death & Disease
- TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
- (2016) Florent Dufour et al. Oncotarget
- Discovery and clinical introduction of first-in-class imipridone ONC201
- (2016) Joshua E. Allen et al. Oncotarget
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer
- (2016) Marina Devetzi et al. Scientific Reports
- Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy
- (2015) Minghua Yang et al. Autophagy
- ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer
- (2015) Jie Yang et al. CANCER BIOLOGY & THERAPY
- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
- (2015) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
- (2015) V. V. Prabhu et al. CANCER RESEARCH
- Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages
- (2015) Yan Huang et al. FEBS Journal
- Cell death induced by endoplasmic reticulum stress
- (2015) Raffaella Iurlaro et al. FEBS Journal
- Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer
- (2015) Gopeshwar Narayan et al. GENES CHROMOSOMES & CANCER
- Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity
- (2015) L O'Leary et al. ONCOGENE
- The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway
- (2015) Sung-Chul Lim et al. TUMOR BIOLOGY
- Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5
- (2015) A Fassl et al. Cell Death & Disease
- Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma
- (2015) Kui Wang et al. Advanced Healthcare Materials
- Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
- (2015) Rachana Trivedi et al. Frontiers in Oncology
- Sandwich-Type Au-PEI/DNA/PEI-Dexa Nanocomplex for Nucleus-Targeted Gene Delivery in Vitro and in Vivo
- (2014) Zhenzhen Chen et al. ACS Applied Materials & Interfaces
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. Clinical Lung Cancer
- Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer
- (2014) L. Gottwald et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Viral and Cellular FLICE-Inhibitory Proteins: a Comparison of Their Roles in Regulating Intrinsic Immune Responses
- (2014) J. L. Shisler JOURNAL OF VIROLOGY
- Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
- (2014) Heather A Huet et al. mAbs
- Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth
- (2014) Changyou Li et al. Molecular Oncology
- Non-viral vectors for gene-based therapy
- (2014) Hao Yin et al. NATURE REVIEWS GENETICS
- Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway
- (2014) R Trivedi et al. Cell Death & Disease
- Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Death Receptors DR4 and DR5 in Human Nonmelanoma Skin Cancer
- (2013) Ola M. Omran et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
- (2013) A Meijer et al. BRITISH JOURNAL OF CANCER
- Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells
- (2013) Verena Haselmann et al. GASTROENTEROLOGY
- Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
- (2013) Diego De Miguel et al. MOLECULAR PHARMACEUTICS
- Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery
- (2013) Eike Gallmeier et al. PLoS One
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis
- (2012) Syam Prakash Somasekharan et al. APOPTOSIS
- Regulation of the human TRAIL gene
- (2012) Joshua E. Allen et al. CANCER BIOLOGY & THERAPY
- Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
- (2012) Nicholas S. Wilson et al. CANCER CELL
- Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors
- (2012) Hairong Cheng et al. CELL CYCLE
- Control of FLIPL expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells
- (2012) R Yerbes et al. CELL DEATH AND DIFFERENTIATION
- Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS–JNK–CHOP-mediated upregulation of death receptors
- (2012) Bokyung Sung et al. FREE RADICAL BIOLOGY AND MEDICINE
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
- (2012) V. Subbiah et al. MOLECULAR CANCER THERAPEUTICS
- TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
- (2012) Francois Gonzalvez et al. MOLECULAR CELL
- MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation
- (2012) G. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL
- (2012) M Grunert et al. Cell Death & Disease
- Zyflamend Sensitizes Tumor Cells to TRAIL-Induced Apoptosis Through Up-Regulation of Death Receptors and Down-Regulation of Survival Proteins: Role of ROS-Dependent CCAAT/Enhancer-Binding Protein-Homologous Protein Pathway
- (2011) Ji Hye Kim et al. ANTIOXIDANTS & REDOX SIGNALING
- Effect of anti-DR5 and chemotherapy on basal-like breast cancer
- (2011) Patsy G. Oliver et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
- (2011) Pamela M. Holland CANCER LETTERS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Wogonin and Related Natural Flavones Overcome Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein Resistance of Tumors by Down-regulation of c-FLIP Protein and Up-regulation of TRAIL Receptor 2 Expression
- (2011) Jie Ding et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells
- (2011) Yuko Kojima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2
- (2011) M.E.D. Chamuleau et al. LEUKEMIA RESEARCH
- The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma
- (2011) Jin Li et al. NANOTECHNOLOGY
- Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types
- (2010) Paula J. Kaplan-Lefko et al. CANCER BIOLOGY & THERAPY
- BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane
- (2010) Z T Schug et al. CELL DEATH AND DIFFERENTIATION
- Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
- (2010) L. Kriegl et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells
- (2009) Takeshi Hori et al. CANCER LETTERS
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
- (2009) S. Macher-Goeppinger et al. CLINICAL CANCER RESEARCH
- Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines
- (2009) Yuko Akazawa et al. GASTROENTEROLOGY
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
- (2009) Tom M. Ganten et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
- (2009) T. A. Luster et al. MOLECULAR CANCER THERAPEUTICS
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions
- (2009) Patrizia Marini et al. Radiation Oncology
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
- (2008) A. Yada et al. ANNALS OF ONCOLOGY
- Sp1-Mediated TRAIL Induction in Chemosensitization
- (2008) J. Xu et al. CANCER RESEARCH
- Six1 Overexpression in Mammary Cells Induces Genomic Instability and Is Sufficient for Malignant Transformation
- (2008) R. D. Coletta et al. CANCER RESEARCH
- Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
- (2008) C Adams et al. CELL DEATH AND DIFFERENTIATION
- Nonviral Vectors for Gene Delivery
- (2008) Meredith A. Mintzer et al. CHEMICAL REVIEWS
- Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
- (2008) H. Jin et al. CLINICAL CANCER RESEARCH
- Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11
- (2008) P. G. Oliver et al. CLINICAL CANCER RESEARCH
- Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
- (2008) Virginie Granci et al. EUROPEAN JOURNAL OF CANCER
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started